Natural killer cells inhibit breast cancer cell invasion through downregulation of urokinase‑type plasminogen activator

Jin,Hao; Choi,Hyojeong; Kim,Eun‑Sook; Lee,Hwan Hee; Cho,Hyosun; Moon,Aree

doi:10.3892/or.2020.7840

Natural killer cells inhibit breast cancer cell invasion through downregulation of urokinase‑type plasminogen activator

Authors:
- Hao Jin
- Hyojeong Choi
- Eun‑Sook Kim
- Hwan Hee Lee
- Hyosun Cho
- Aree Moon
View Affiliations

Affiliations: Duksung Innovative Drug Center, College of Pharmacy, Duksung Women's University, Seoul 132‑714, Republic of Korea
Published online on: November 6, 2020 https://doi.org/10.3892/or.2020.7840
Pages: 299-308

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) is one of the most aggressive types of breast cancer, and there is no effective therapeutic target to date. Natural killer (NK) cells are functionally diverse lymphocytes that recognize and kill cancer cells. Although it is clear that NK cells exert antitumor activity in the tumor microenvironment, their role in the aggressive progression of TNBC has not been elucidated in detail. In the present study, we investigated the effect of NK cells on MDA‑MB‑231 TNBC cells using an indirect co‑culture system. The invasive phenotype of MDA‑MB‑231 cells was significantly inhibited by co‑culture with NK cells. Notably, the expression of urokinase‑type plasminogen activator (uPA) was markedly reduced by NK cells. Cytokine array analysis showed that the levels of interleukin (IL)‑10, IL‑6, IL‑8, C‑C motif ligand (CCL)5, and CCL2 were increased in conditioned media from the co‑cultured cells. Among these cytokines, IL‑6 played a crucial role in the NK cell‑induced uPA downregulation and inhibition of the invasive phenotype of MDA‑MB‑231 cells and Hs578T cells. We analyzed the Gene Expression Profiling Interactive Analysis database for correlations between IL‑6 and uPA with the overall survival of breast cancer patients. The Kaplan‑Meier survival analysis revealed that a low IL‑6/uPA ratio was associated with the poor survival of breast cancer patients, suggesting it as an important factor for determining the overall survival of breast cancer patients. Taken together, our findings demonstrate that NK cells in the tumor microenvironment inhibit the invasiveness of TNBC cells through the IL‑6‑mediated inhibition of uPA.

View Figures

View References

1	Bouchardy C, Fioretta G, Verkooijen HM, Vlastos G, Schaefer P, Delaloye JF, Neyroud-Caspar I, Balmer Majno S, Wespi Y, Forni M, et al: Recent increase of breast cancer incidence among women under the age of forty. Br J Cancer. 96:1743–1746. 2007. View Article : Google Scholar
2	Curado MP: Breast cancer in the world: Incidence and mortality. Salud Publica Mex. 53:372–384. 2011.
3	Redig AJ and McAllister SS: Breast cancer as a systemic disease: A view of metastasis. J Intern Med. 274:113–126. 2013. View Article : Google Scholar
4	Nakhjavani M, Hardingham JE, Palethorpe HM, Price TJ and Townsend AR: Druggable molecular targets for the treatment of triple negative breast cancer. J Breast Cancer. 22:341–361. 2019. View Article : Google Scholar
5	Bayraktar S and Glück S: Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat. 138:21–35. 2013. View Article : Google Scholar
6	Kenny PA, Nelson CM and Bissell MJ: The Ecology of Tumors: By perturbing the microenvironment, wounds and infection may be key to tumor development. Scientist. 20:302006.
7	Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, et al: Role of tumor microenvironment in tumorigenesis. J Cancer. 8:761–773. 2017. View Article : Google Scholar
8	Wu J and Lanier LL: Natural killer cells and cancer. Adv Cancer Res. 90:127–156. 2003. View Article : Google Scholar
9	Cheng M, Chen Y, Xiao W, Sun R and Tian Z: NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 10:230–252. 2013. View Article : Google Scholar
10	Mandal A and Viswanathan C: Natural killer cells: In health and disease. Hematol Oncol Stem Cell Ther. 8:47–55. 2015. View Article : Google Scholar
11	López-Soto A, Gonzalez S, Smyth MJ and Galluzzi L: Control of metastasis by NK cells. Cancer Cell. 32:135–154. 2017. View Article : Google Scholar
12	Guillerey C, Huntington ND and Smyth MJ: Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 17:1025–1036. 2016. View Article : Google Scholar
13	Jiao Y, Huntington ND, Belz GT and Seillet C: Type 1 innate lymphoid cell biology: Lessons learnt from natural killer cells. Front Immunol. 7:4262016. View Article : Google Scholar
14	Sun Y, Yao Z, Zhao Z, Xiao H, Xia M, Zhu X, Jiang X and Sun C: Natural killer cells inhibit metastasis of ovarian carcinoma cells and show therapeutic effects in a murine model of ovarian cancer. Exp Ther Med. 16:1071–1078. 2018.
15	Aznavoorian S, Murphy AN, Stetler-Stevenson WG and Liotta LA: Molecular aspects of tumor cell invasion and metastasis. Cancer. 71:1368–1383. 1993. View Article : Google Scholar
16	Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 10:415–433. 2000. View Article : Google Scholar
17	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar
18	Song H, Ki SH, Kim SG and Moon A: Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells. Cancer Res. 66:10487–10496. 2006. View Article : Google Scholar
19	Lee S, Lee E, Ko E, Ham M, Lee HM, Kim ES, Koh M, Lim HK, Jung J, Park SY and Moon A: Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9. Cancer Lett. 437:25–34. 2018. View Article : Google Scholar
20	Pepper MS: Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 21:1104–1117. 2001. View Article : Google Scholar
21	Kumari S and Malla R: New insight on the role of plasminogen receptor in cancer progression. Cancer Growth Metastasis. 8:35–42. 2015. View Article : Google Scholar
22	Lijnen HR: Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc). 67:92–98. 2002. View Article : Google Scholar
23	Wilkins-Port CE, Higgins SP, Higgins CE, Kobori-Hotchkiss I and Higgins PJ: Complex regulation of the pericellular proteolytic microenvironment during tumor progression and wound repair: Functional interactions between the serine protease and matrix metalloproteinase cascades. Biochem Res Int. 2012:4543682012. View Article : Google Scholar
24	Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V and Brünner N: Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis. 14:297–307. 1996.
25	Crippa MP: Urokinase-type plasminogen activator. Int J Biochem Cell Biol. 39:690–694. 2007. View Article : Google Scholar
26	Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, et al: Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci Rep. 7:93882017. View Article : Google Scholar
27	Mahmood N, Mihalcioiu C and Rabbani SA: Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications. Front Oncol. 8:242018. View Article : Google Scholar
28	Moon A, Kim MS, Kim TG, Kim SH, Kim HE, Chen YQ and Kim HR: H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: A role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer. 85:176–181. 2000. View Article : Google Scholar
29	Stepanova V, Jayaraman PS, Zaitsev SV, Lebedeva T, Bdeir K, Kershaw R, Holman KR, Parfyonova YV, Semina EV, Beloglazova IB, et al: Urokinase-type plasminogen activator (uPA) promotes angiogenesis by attenuating proline-rich homeodomain protein (PRH) transcription factor activity and de-repressing vascular endothelial growth factor (VEGF) receptor expression. J Biol Chem. 291:15029–15045. 2016. View Article : Google Scholar
30	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar
31	Lampelj M, Arko D, Cas-Sikosek N, Kavalar R, Ravnik M, Jezersek-Novakovic B, Dobnik S, Dovnik NF and Takac I: Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer-correlation with traditional prognostic factors. Radiol Oncol. 49:357–364. 2015. View Article : Google Scholar
32	Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C and Harbeck N: uPA and PAI-1 in breast cancer: Review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem. 45:31–45. 2008. View Article : Google Scholar
33	Duffy MJ, McGowan PM, Harbeck N, Thomssen C and Schmitt M: uPA and PAI-1 as biomarkers in breast cancer: Validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 16:4282014. View Article : Google Scholar
34	Fauriat C, Long EO, Ljunggren HG and Bryceson YT: Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 115:2167–2176. 2010. View Article : Google Scholar
35	Sun W, Liu DB, Li W, Zhang LL, Long GX, Wang JF, Mei Q and Hu GQ: Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9. Int J Oncol. 44:1551–1560. 2014. View Article : Google Scholar
36	Razidlo GL, Burton KM and McNiven MA: Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem. 293:11143–11153. 2018. View Article : Google Scholar
37	Gopinathan G, Milagre C, Pearce OM, Reynolds LE, Hodivala-Dilke K, Leinster DA, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR and Balkwill F: Interleukin-6 stimulates defective angiogenesis. Cancer Res. 75:3098–3107. 2015. View Article : Google Scholar
38	Wegiel B, Bjartell A, Culig Z and Persson JL: Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer. 122:1521–1529. 2008. View Article : Google Scholar
39	Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL and Shih IeM: Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res. 10:6432–6436. 2004. View Article : Google Scholar
40	Leu CM, Wong FH, Chang C, Huang SF and Hu CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 22:7809–7818. 2003. View Article : Google Scholar
41	Ulisse S, Baldini E, Sorrenti S and D'Armiento M: The urokinase plasminogen activator system: A target for anti-cancer therapy. Curr Cancer Drug Targets. 9:32–71. 2009. View Article : Google Scholar
42	Sidenius N and Blasi F: The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22:205–222. 2003. View Article : Google Scholar